Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer
Interface Focus · 2019-04-06 · 9 (2) · 20180077
DOI: 10.1098/rsfs.2018.0077 ↗Abstract
The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).
EUVIMED